Valbiotis SA (EPA:ALVAL)

Market Cap	16.75M
Revenue (ttm)	474.00K
Net Income (ttm)	-11.12M
Shares Out	23.66M
EPS (ttm)	-0.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	111,018
Average Volume	732,170
Open	0.7100
Previous Close	0.7100
Day's Range	0.7040 - 0.7370
52-Week Range	0.5350 - 1.6760
Beta	-0.41
RSI	50.08
Earnings Date	Dec 29, 2025

About Valbiotis

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. The company has a partnership with Leiden University, Vanderbilt University, INAF, CarMeN Laborato...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 44
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALVAL

Financial Performance

In 2024, Valbiotis's revenue was 176,000, a decrease of -96.28% compared to the previous year's 4.73 million. Losses were -10.03 million, 36.1% more than in 2023.